针对类风湿性关节炎中的细胞迁移
Targeting cell migration in rheumatoid arthritis.
作者信息
Asquith Darren L, Bryce Steven A, Nibbs Robert J B
机构信息
Centre for Immunobiology, Institute of Infection, Immunity & Inflammation, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
出版信息
Curr Opin Rheumatol. 2015 Mar;27(2):204-11. doi: 10.1097/BOR.0000000000000150.
PURPOSE OF REVIEW
To provide an update of past failures, future prospects and key challenges facing the therapeutic targeting of chemokines and their receptors in rheumatoid arthritis.
RECENT FINDINGS
Clinical trials in rheumatoid arthritis have been undertaken with small molecule antagonists or neutralizing antibodies targeting CCR1, CCR5 and CXCL10. Some encouraging results have emerged. Laboratory and clinical research has identified CCL19, CXCL13 and CXCL12, and their receptors, as potential future targets. Developments in our appreciation of posttranslational chemokine modification highlight the complexity of chemokine networks operating in inflamed tissues, and the substantial gaps in existing knowledge.
SUMMARY
Despite previous disappointments, there are still reasons to be optimistic that drugs targeting chemokines and their receptors could be developed for the treatment of rheumatoid arthritis. However, a deeper understanding of the chemokine networks at work in inflamed joints is a necessary prerequisite.
综述目的
更新既往在类风湿关节炎中靶向趋化因子及其受体治疗的失败经验、未来前景和面临的关键挑战。
最新发现
针对CCR1、CCR5和CXCL10的小分子拮抗剂或中和抗体已在类风湿关节炎中进行了临床试验。已出现一些令人鼓舞的结果。实验室和临床研究已确定CCL19、CXCL13和CXCL12及其受体为潜在的未来靶点。我们对趋化因子翻译后修饰认识的进展凸显了在炎症组织中运作的趋化因子网络的复杂性以及现有知识的重大空白。
总结
尽管先前令人失望，但仍有理由乐观地认为，可开发出靶向趋化因子及其受体的药物用于治疗类风湿关节炎。然而，深入了解炎症关节中起作用的趋化因子网络是必要的先决条件。
Zotero 插件